These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 33921181)

  • 21. [Next generation of anti-immune checkpoints antibodies].
    Bonnefoy N; Olive D; Vanhove B
    Med Sci (Paris); 2019 Dec; 35(12):966-974. PubMed ID: 31903901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV.
    Benito JM; Restrepo C; García-Foncillas J; Rallón N
    Front Immunol; 2023; 14():1270881. PubMed ID: 38130714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors.
    Catalano M; Shabani S; Venturini J; Ottanelli C; Voltolini L; Roviello G
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
    Jafari S; Molavi O; Kahroba H; Hejazi MS; Maleki-Dizaji N; Barghi S; Kiaie SH; Jadidi-Niaragh F
    Cell Mol Life Sci; 2020 Oct; 77(19):3693-3710. PubMed ID: 32006051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
    Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
    Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VISTA immune regulatory effects in bypassing cancer immunotherapy: Updated.
    Mortezaee K; Majidpoor J; Najafi S
    Life Sci; 2022 Dec; 310():121083. PubMed ID: 36265568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 Inhibitors for the Treatment of Prostate Cancer.
    Santoni M; Massari F; Cheng L; Cimadamore A; Scarpelli M; Montironi R; Lopez-Beltran A
    Curr Drug Targets; 2020; 21(15):1558-1565. PubMed ID: 32516098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Targets of Immunotherapy in Gynecologic Cancer.
    Cheng H; Zong L; Kong Y; Gu Y; Yang J; Xiang Y
    Onco Targets Ther; 2020; 13():11869-11882. PubMed ID: 33239889
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
    Elia AR; Caputo S; Bellone M
    Front Immunol; 2018; 9():1786. PubMed ID: 30108594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. B7-H3: a robust target for immunotherapy in prostate cancer.
    Pulido R; López JI; Nunes-Xavier CE
    Trends Cancer; 2024 Jul; 10(7):584-587. PubMed ID: 38839545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy.
    Yu L; Sun M; Zhang Q; Zhou Q; Wang Y
    Front Immunol; 2022; 13():982026. PubMed ID: 36159789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of B7 family checkpoint proteins in cervical cancer.
    Zong L; Gu Y; Zhou Y; Kong Y; Mo S; Yu S; Xiang Y; Chen J
    Mod Pathol; 2022 Jun; 35(6):786-793. PubMed ID: 34848831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
    Zahm CD; Johnson LE; McNeel DG
    Cancer Immunol Immunother; 2019 Oct; 68(10):1661-1669. PubMed ID: 31606777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High expression of immune checkpoints is associated with the TIL load, mutation rate and patient survival in colorectal cancer.
    Kitsou M; Ayiomamitis GD; Zaravinos A
    Int J Oncol; 2020 Jul; 57(1):237-248. PubMed ID: 32468013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
    Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
    Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
    Huang L; He J
    Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
    Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
    Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.